Summit Enterprise Value Over E B I T D A from 2010 to 2025
| SMMT Stock | USD 20.26 0.43 2.08% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 40.7 K | Current Value 42.7 K | Quarterly Volatility 14.3 K |
Check Summit Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Summit Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 109.6 M, Selling General Administrative of 63.6 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 1.3 K, Dividend Yield of 0.0 or PTB Ratio of 31.34. Summit financial statements analysis is a perfect complement when working with Summit Therapeutics Valuation or Volatility modules.
Summit | Enterprise Value Over E B I T D A |
Latest Summit Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Summit Therapeutics PLC over the last few years. It is Summit Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Summit Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Summit Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 5,131 | |
| Geometric Mean | 65.80 | |
| Coefficient Of Variation | 278.57 | |
| Mean Deviation | 9,138 | |
| Median | (8.86) | |
| Standard Deviation | 14,294 | |
| Sample Variance | 204.3M | |
| Range | 45.2K | |
| R-Value | 0.60 | |
| Mean Square Error | 139.6M | |
| R-Squared | 0.36 | |
| Significance | 0.01 | |
| Slope | 1,807 | |
| Total Sum of Squares | 3.1B |
Summit Enterprise Value Over E B I T D A History
About Summit Therapeutics Financial Statements
Summit Therapeutics shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Summit Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Summit Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Summit Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 40.7 K | 42.7 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Summit Stock Analysis
When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.